Gulf International Bank UK Ltd Has $3.16 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Gulf International Bank UK Ltd lessened its holdings in Edwards Lifesciences Co. (NYSE:EW) by 4.2% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 47,924 shares of the medical research company’s stock after selling 2,126 shares during the quarter. Gulf International Bank UK Ltd’s holdings in Edwards Lifesciences were worth $3,162,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Clarity Capital Partners LLC boosted its position in shares of Edwards Lifesciences by 16.7% in the third quarter. Clarity Capital Partners LLC now owns 9,169 shares of the medical research company’s stock worth $605,000 after buying an additional 1,312 shares during the period. Impax Asset Management Group plc boosted its position in shares of Edwards Lifesciences by 66.2% in the third quarter. Impax Asset Management Group plc now owns 12,964 shares of the medical research company’s stock worth $855,000 after buying an additional 5,164 shares during the period. QRG Capital Management Inc. boosted its position in Edwards Lifesciences by 66.6% during the third quarter. QRG Capital Management Inc. now owns 77,245 shares of the medical research company’s stock valued at $5,097,000 after purchasing an additional 30,892 shares during the last quarter. Asset Management One Co. Ltd. boosted its position in Edwards Lifesciences by 0.9% during the third quarter. Asset Management One Co. Ltd. now owns 239,392 shares of the medical research company’s stock valued at $15,797,000 after purchasing an additional 2,188 shares during the last quarter. Finally, National Pension Service boosted its position in Edwards Lifesciences by 9.2% during the third quarter. National Pension Service now owns 1,584,579 shares of the medical research company’s stock valued at $104,566,000 after purchasing an additional 133,182 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling

In related news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the sale, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the sale, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 41,250 shares of company stock valued at $2,746,988. 1.27% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on EW. Baird R W cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 25th. JPMorgan Chase & Co. boosted their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Citigroup reduced their price target on Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a research report on Tuesday, October 1st. Wolfe Research raised Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research report on Monday, July 29th. Finally, UBS Group reduced their price target on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a research report on Tuesday, September 10th. Seventeen analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $75.67.

Edwards Lifesciences Stock Down 1.4 %

NYSE:EW opened at $65.75 on Thursday. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $39.61 billion, a P/E ratio of 9.49, a P/E/G ratio of 3.80 and a beta of 1.12. The stock’s fifty day simple moving average is $67.75 and its 200-day simple moving average is $77.18.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 22.56% and a net margin of 70.82%. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same period last year, the company earned $0.59 EPS. The firm’s revenue was up 8.9% on a year-over-year basis. Equities research analysts expect that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.